Literature DB >> 26537791

The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.

Ufuk Barış Kuzu1, Bülent Ödemiş2, Nuretdin Suna2, Hakan Yıldız2, Erkan Parlak2, Selçuk Dişibeyaz2, Serkan Torun2, Muhammet Yener Akpınar2, Orhan Coşkun2, Nesrin Turhan3, Mahmut Yüksel2, Ertuğrul Kayaçetin2.   

Abstract

PURPOSE: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease. Cholangiocarcinoma (CCA) is one of the feared complications of PSC. In our study, we aim to establish the success of brush cytology and CA 19-9 in putting the diagnosis of CCA.
METHODS: The data of 30 PSC patients was retrospectively screened whom had brush cytology performed due to dominant strictures. The definitive diagnosis was established by histopathological examination or via radiological/clinic follow-up for at least 12 months.
RESULTS: A total of four patients were excluded from the study. Twenty-six patients diagnosed with PSC, six of which were also diagnosed with CCA, were included in the study. The sensitivity and the specificity of the brush cytology in the diagnosis of CCA in PSC patients were 66.7 and 95%, respectively. CA 19-9 had high correlation with bilirubin level. The optimal level of CA 19-9 in the diagnosis of CCA was determined to be 138.5 U/ml. Superiority of Ramage scoring over CA 19-9 in the diagnosis of CCA in PSC patients was not established (sensitivity and specificity were 50%, 94.7% and 83.3%, 85%, respectively).
CONCLUSION: Brush cytology has moderate sensitivity in differentiating strictures in PSC patients. CA 19-9 has high sensitivity but bilirubin level can affect the CA 19-9. Therefore, advanced techniques and parameters are needed for detecting CCA in PSC patients.

Entities:  

Keywords:  Brush cytology; CA 19-9; Cholangiocarcinoma; Primary sclerosing cholangitis

Mesh:

Substances:

Year:  2016        PMID: 26537791     DOI: 10.1007/s12029-015-9777-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  47 in total

1.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

Review 3.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

4.  Primary sclerosing cholangitis.

Authors:  E R Dickson; N F LaRusso; R H Wiesner
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

5.  Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures.

Authors:  M Rabinovitz; A B Zajko; T Hassanein; B Shetty; K M Bron; R R Schade; J S Gavaler; G Block; D H Van Thiel; A Dekker
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity.

Authors:  Leena Halme; Johanna Arola; Kirsti Numminen; Leena Krogerus; Heikki Mäkisalo; Martti Färkkilä
Journal:  Liver Int       Date:  2011-11-15       Impact factor: 5.828

8.  Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  J K Ramage; A Donaghy; J M Farrant; R Iorns; R Williams
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

9.  Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.

Authors:  A Nakeeb; P A Lipsett; K D Lillemoe; M K Fox-Talbot; J Coleman; J L Cameron; H A Pitt
Journal:  Am J Surg       Date:  1996-01       Impact factor: 2.565

Review 10.  Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  T H Karlsen; M Vesterhus; K M Boberg
Journal:  Aliment Pharmacol Ther       Date:  2013-12-29       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.